Rational design, synthesis, and serine protease inhibitory activity of a novel P1-argininal derivative featuring a conformationally constrained P2-P3 bicyclic lactam moiety

Bioorganic and Medicinal Chemistry Letters

Volumn 7, Issue 3, 1997, Pages 331-336

  Tamura, Susan Y ^a   Goldman, Erick A ^a   Brunck, Terence K ^a   Ripka, William C ^a   Semple, J Edward ^a  

^a Dendreon   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE DERIVATIVE; BLOOD CLOTTING FACTOR 10A; CVS 1862; SERINE PROTEINASE INHIBITOR; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; TRYPSIN; UNCLASSIFIED DRUG;

ARTICLE; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; HEMOSTASIS; MASS SPECTROMETRY; MOLECULAR MODEL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 0031552086     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(97)00004-8     Document Type: Article

References (61)

1. 1. (a) Dedicated with genuine affection and respect to Professor Madeleine M. Joullie, Department of Chemistry, University of Pennsylvania, on the occasion of her 70th birthday. (b) Presented in part at the Gordon Research Conference on Heterocyclic Chemistry, New Hampshire, July 7-12, 1996.
2. 2. (a) Colman, R. W.; Marder, V. J.; Salzman, E.; W. Hirsch, J. In Hemostasis and Thrombosis: Basic Principles and Clinical Practice; 3rd ed.; Colman, R. W.; Hirsch, J.; Marder, V. J.; Salzman, E. W.; Eds.; J. B. Lippincott: Philadelphia, 1994; 3.
3. 2. (a) Colman, R. W.; Marder, V. J.; Salzman, E.; W. Hirsch, J. In Hemostasis and Thrombosis: Basic Principles and Clinical Practice; 3rd ed.; Colman, R. W.; Hirsch, J.; Marder, V. J.; Salzman, E. W.; Eds.; J. B. Lippincott: Philadelphia, 1994; 3.
4. (b) Mann, K. G. ibid., 184.
5. (c) Colman, R. W.; Cook, J.; Niewiarowski, S. ibid., 508.
6. (d) Edit, J. F.; Allison, P.; Noble, S.; Ashton, J.; Golino, P.; McNard, J.; Buja, L. M.; Willerson, J. T. J. Clin. Invest. 1989, 84, 18.
7. 3. (a) Bazan, J. F. Nature (London) 1996, 380, 21.
8. (b) Maraganore, J. M. Thromb. Haemostasis 1993, 70, 208.
9. (c) Tans, G.; Rosing, J.; Thomassen, M. C.; Heeb, M. J.; Zwaal, R. F.; Griffin, J. H. Blood 1991, 77, 2641.
10. 4. (a) Scarborough, R. M. In Ann. Rep. Med. Chem. Bristol, J. A., Ed.; Academic Press: San Diego, 1995; vol. 30, 71.
11. (b) Harker, L. A.; Hanson, S. R.; Kelly, A. B. Thromb. Haemost. 1995, 74, 464.
12. (c) Lyle, T. A. Perspectives in Drug Discovery and Design 1993, 1, 453.
13. 1 see: Balasubramanian, B. N., Ed.; Advances in the Design and Development of Thrombin Inhibitors. Bioorg. Med. Chem. 1995, 3, 999-1156.
14. (b) Stone, S. R. Trends in Cardiovasc. Med. 1995, 5, 134.
15. (c) Lefkovits, J.; Topol, E. J. Circulation 1994, 90, 1522.
16. (d) Tapparelli, C.; Meternich, R.; Ehrhardt, C.; Cook, N. S. Trends in Pharm. Science 1993, 14, 366.
17. 6. (a) Semple, J. E.; Rowley, D. C.; Brunck, T. K.; Ripka, W. C. Bioorg. Med. Chem. Lett. 1997, 7, in press.
18. (b) Obst, U.; Gramlich, V.; Diederich, F.; Weber, L.; Banner, D. W. Angew. Chem. Intl. Ed. Engl., 1995, 34, 1739.
19. (c) Senokuchi, K.; Nakai, H.; Nakayama, Y.; Odagaki, Y.; Sakaki, K.; Kato, M.; Maruyama, T.; Miyazaki, T.; Ito, H.; Kamiyasu, K.; Kim, S.; Kawamura, M.; Hamanaka, N. J. Med. Chem. 1995, 38, 4508.
20. (d) Misra, R. N.; Kelly, Y. F.; Brown, B. R.; Roberts, D. G. M.; Chong, S.; Seiler, S. M. Bioorg. Med. Chem. Lett. 1994, 4, 2165.
21. 7. (a) Costanzo, M. J.; Maryanoff, B. E.; Hecker, L. R.; Schott, M. R.; Yabut, S. C.; Zhang, H.-C.; Andrade-Gordon, P.; Kauffman, J., A.; Lewis, J. M.; Krishnan, R.; Tulinsky, A. J. Med. Chem. 1996, 39, 3039.
22. (b) Shuman, R. T.; Rothenberger, R. B.; Campbell, C. S.; Smith, G. F.; Gifford-Moore, D. S.; Paschal, J. W.; Gesellchen, P. D. J. Med. Chem. 1995, 38, 4446.
23. (c) Bagdy, D.; Barabas, E.; Bajusz, S.; Szell, E. Thromb. Haemostasis 1992, 67, 325.
24. (d) Bajusz, S.; Szell, E.; Bagdy, D.; Barabas, E.; Horvath, G.; Dioszegi, M.; Fittler, Z.; Szabo, G.; Juhasz, A.; Tomori, E.; Szilagyi, G. J. Med. Chem. 1990, 33, 1729.
25. (e) Balasubramanian, N.; St. Laurent, D. R.; Federici, M. E.; Meanwell, N. A.; Wright, J. J.; Schumacher, W. A.; Seiler, S. M. J. Med. Chem. 1993, 36, 300.
26. 8. (a) Robl, J. A.; Cimarusti, M. P.; Simpkins, L. M.; Brown, B.; Ryono, D. E.; Bird, J. E.; Asaad, M. M.; Schaeffer, T. R.; Trippodo, N. C. J. Med. Chem. 1996, 39, 494.
27. (b) Robl, J. A.; Karanewsky, D. S.; Asaad, M. M. Tetrahedron Lett. 1995, 36, 1593.
28. (c) Colombo, L.; Di Giacomo, M.; Scolastico, C.; Manzoni, L.; Belvisi, L.; Molteni, V. Tetrahedron Lett. 1995, 36, 625.
29. (d) Curran T. P.; McEnaney, P. M. Tetrahedron Lett. 1995, 36, 191.
30. (e) Skiles, J. W.; Sorcek, R.; Jacober, S.; Miao, C.; Mui, P. W.; Mc Nell, D.; Rosenthal, A. S. Bioorg. Med. Chem. Lett. 1993, 3, 773.
31. (f) Freidinger, R. M.; Perlow, D. S.; Veber, D. F. J. Org. Chem 1982, 47, 104.
32. 9. (a) Fairlie, D. P.; Abbenante, G.; March, D. R. Curr. Med. Chem. 1995, 2, 654.
33. (b) Lombart, H.-G.; Lubell, W. D. J. Org. Chem. 1994, 59, 6147.
34. (c) Freidinger, R. M.; Veber, D. F.; Perlow, D. S.; Brooks, J. R.; Saperstein, R. Science 1980, 210, 656.
35. 10. (a) Semple, J. E.; Rowley, D. C.; Brunck, T. K.; Ha-Uong, T.; Minami, N. K.; Owens, T. D.; Tamura, S. Y.; Goldman, E. A.; Siev, D. V.; Ardecky, R. J.; Carpenter, S. H.; Ge, Y.; Richard, B. M.; Nolan, T. G.; Håkanson, K; Tulinsky, A.; Nutt, R. F.; Ripka, W. C. J. Med. Chem. 1996, 39, 4531.
36. (b) Semple, J. E.; Ardecfcy, R. J.; Nutt, R. F.; Ripka, W. C.; Rowley, D. C.; Lim-Wilby, M. S.; Brunck, T. K. PCT Patent Application WO 95/35311, 1995.
37. 11. Vlasuk, G. P.; Webb, T. R.; Pearson, D. A.; Abelman, M. A. U.S. Patent 5492895, 1996.
38. 12.(a) Cousins, G. R.; Friedrichs, G. S.; Sudo, Y.; Rebello, S. S.; Rote, W. E.; Vlasuk, G. P.; Nolan, T. G.; Mendoza, C.; Lucchesi, B. R. Circulation 1996, 94, 1705.
39. (b) Synthetic routes to CVS 1123: Ardecky, R. J.; Carpenter, S. H.; Ge, Y.; Leon, P.; Nutt, R. F.; Ripka, W. C.; Rowley, D. C.; Semple, J. E.; Shamblin, B. S.; Tamura, S. Y.; Weinhouse, M. I.; Lim-Wilby, M. S. L. Manuscript in preparation.
40. 13.(a) Malley, M. F.; Tabernero, L.; Chang, C. Y.; Ohringer, S. L.; Roberts, D. G. M.; Das, J.; Sack, J. S. Protein Sci. 1996, 5, 221.
41. (b) Håkansson, K.; Tulinsky, A.; Abelman, M. M.; Miller, T. A.; Vlasuk, G. P.; Bergum, P. W.; Lim-Wilby, M. S. L.; Brunck, T. K. Bioorg. Med. Chem. 1995, 3, 1009.
42. (c) Stubbs, M. T.; Bode, W. Trends in Biochem. Science 1995, 20, 23.
43. (d) Weber, P C.; Lee, S.-L.; Lewandowski, F. A.; Schadt, M. C.; Chang, C-H.; Kettner, C. A. Biochemistry 1995, 34, 3750.
44. (e) Banner, D. W.; Hadvary, P. J. Biol. Chem. 1991, 266, 20085.
45. (f) Bode, W.; Mayr, I.; Baumann, U.; Huber, R.; Stone, S. R.; Hofsteenge, J. EMBO J. 1989, 8, 3467.
46. 14. Iwanowicz, E. J.; Lau, W. F.; Lin, J.; Roberts, D. G. M.; Seiler, S. M. R J. Med. Chem. 1994, 37, 2122.
47. 15. Kimball, S. D. Blood Coag. Fibrinol. 1995, 6, 511.
48. 16. (a) Morgan, B. A.; Gainor, J. A. In Ann. Rep. Med. Chem. Allen, R. C., Ed.; Academic Press: San Diego, 1989; vol. 24, Chapter 26, pp 243-252.
49. (b) Rich, D. H. in Comprehensive Medicinal Chemistry; Hansch, C.; Sammes, P. G.; Taylor, J. B., Eds.; Pergamon Press: Oxford, 1990; Vol. 2, Chapter 8.
50. (c) Spatola, A. F. in Chemistry and Biochemistry of Amino Acids, Peptides ands Proteins; Weinstein, B., Ed.; Marcel Dekker: New York, 1983; vol. 7, Chapter 5.
51. 17. All new compounds were characterized by full spectroscopic (NMR, IR, low/high resolution MS) data. Yields refer to spectroscopically and chromatographically homogenous (≥95% by HPLC, TLC) materials.
52. 18.(a) Tamura, S. Y.; Semple, J. E.; Ardecky, R. J.; Leon, P.; Carpenter, S. H.; Ge, Y.; Shamblin, B. M.; Weinhouse, M. I.; Ripka, W. C.; Nutt, R. F. Tetrahedron Lett. 1996, 37, 4109.
53. (b) Webb, T. R.; Reiner, J. E.; Tamura, S. Y.; Ripka, W. C.; Dagnino, R.; US Patent 5514777, 1996.
54. 19. The intermediate glutamic acid derivative 6 is commercially available, however its very high price led us to develop the protocol described, which is operationally very convenient and proceeds from reasonably priced starting material 5.
55. 20. (a) Ho, P. T.; Hgu, K. J. Org. Chem. 1993, 58, 2313.
56. (b) Fukuyama, T.; Lin, S.-C; Li, L. J. Am. Chem. Soc. 1990, 112, 7050.
57. 21. (a) Baldwin, J. E.; Freeman, R. T.; Lowe, C.; Schofield, C. J.; Lee, E. Tetrahedron 1989, 45, 4537.
58. (b) Subasinghe, N. L.; Bontems, R. J.; McIntee, E.; Mishra, R. K.; Johnson, R. L. J. Med. Chem. 1993, 36, 2356.
59. (c) Nagai, U.; Sato, K.; Nakamura, R.; Kato, R. Tetrahedron, 1993, 49, 3577.
60. (d) Bach, A. C; Markwalder, J. A.; Ripka, W. C. Int. J. Peptide Protein Res. 1991, 38, 314.
61. 22. The in vitro enzyme assays were performed according to the protocols described in reference 10a.